This phase Ib trial is assessing the safety of a new drug (blinatumomab) for the treatment of indolent Non-Hodgkin's Lymphoma that has gotten worse or not responded to prior therapy.
This trial is treating patients with indolent Non-Hodgkin's Lymphoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
The primary objective of this trial is to assess the safety and tolerability of blinatumomab, administered subcutaneously every 12 (q12h) and 24 (q24h) hours.
Recruiting Hospitals Read More